![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
弗雷曼祖马布:为儿童首次获得批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. pdd@adis.com.
Paediatric drugs
|September 29, 2025
概括
针对色素基因相关的单克隆抗体Fremanezumab现在已批准用于预防6至17岁儿童患者的偶发性偏头痛. 这标志着对年轻人偏头痛治疗的重要里程碑.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 偏头痛是一种复杂的神经疾病,影响全球数百万人.
- 素基因相关 (CGRP) 在偏头痛病理生理学中起着至关重要的作用.
- 儿童偏头痛的现有治疗方法存在局限性,需要新的治疗选择.
研究的目的:
- 总结一个针对CGRP的单克隆抗体fremanezumab的发展.
- 突出了导致弗雷曼祖马布用于偏头痛预防的儿科批准的里程碑.
- 提供弗雷曼尼祖马布从开发到扩展指示的旅程的概述.
主要方法:
- 对 fremanezumab 的临床试验数据和监管机构提交的意见的审查.
- 对针对CGRP的framanezumab的作用机制的分析.
- 对儿科患者群体的药理动力学和药理动力学概况的检查.
主要成果:
- 弗雷曼祖马布是一种人性化的单克隆抗体,可以选择性地向CGRP.
- 该药物于2018年获得美国FDA批准用于成人偏头痛预防.
- 在2025年8月,弗雷曼祖马布获得批准用于小儿病患者 (6-17岁,≥45公斤) 的偶发性偏头痛预防.
结论:
- 弗雷曼祖马布在儿科患者的偏头痛管理方面取得了重大进展.
- 针对性抑制CGRP提供了一个新的治疗策略,用于偶发性偏头痛.
- 这项儿科批准扩大了弱势患者群体的治疗选择.
相关概念视频
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
219
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
219
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
188
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
188
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
165
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
165
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
231
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
231
01:26FDA Approved Drugs: Changes to Approved Drugs
214
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
214
01:29Drug Dosing: Infants and Children
226
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
226